Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine + lidocaine** is a procedural local anesthesia combination kit marketed as **Point of Care LM 2.2**. The kit combines two amide-type small-molecule local anesthetics, bupivacaine hydrochloride and lidocaine hydrochloride, with topical antiseptic skin-preparation components, isopropyl alcohol and povidone-iodine. Its intended use is to facilitate local or regional anesthesia for surgical, diagnostic, and therapeutic procedures, with the anesthetic effect mediated primarily by reversible blockade of voltage-gated sodium channels in peripheral nerves, thereby preventing initiation and conduction of nerve impulses. The antiseptic components are used for injection-site preparation rather than providing the anesthetic pharmacology. Public context provided indicates distribution by AuroMedics Pharma and use in anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine hydrochloride + isopropyl alcohol + povidone-iodine + lidocaine.